Evidence map›Paper›PMID 33040183›Full record

ArticleHistochemistry and cell biology2021

Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles.

E A Wallnöfer, G C Thurner, C Kremser, H Talasz, M M Stollenwerk, A Helbok, N Klammsteiner, K Albrecht-Schgoer, H Dietrich, W Jaschke and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Histochemistry and cell biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

E A WallnöferDepartment of Radiology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.
G C ThurnerDepartment of Radiology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.
C KremserDepartment of Radiology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.
H TalaszDivision of Clinical Biochemistry, Biocenter, Medical University of Innsbruck, Innrain 80-82, 6020, Innsbruck, Austria.
M M StollenwerkFaculty of Health and Society, Biomedical Laboratory Science, University Hospital MAS, Malmö University, 205 06, Malmö, Sweden.
A HelbokDepartment of Nuclear Medicine, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria.
N KlammsteinerDivision of Histology and Embryology, Department of Anatomy, Histology and Embryology, Medical University of Innsbruck, Müllerstrasse 59, 6020, Innsbruck, Austria.
K Albrecht-SchgoerDepartment of Pharmaceutical Technology, Institute of Pharmacy, Leopold-Franzens-University Innsbruck, Innrain 80-82/IV, 6020, Innsbruck, Austria.
H DietrichCentral Laboratory Animal Facilities, Innsbruck Medical University, Peter-Mayr-Strasse 4a, 6020, Innsbruck, Austria.
W JaschkeDepartment of Radiology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.
P DebbageDivision of Histology and Embryology, Department of Anatomy, Histology and Embryology, Medical University of Innsbruck, Müllerstrasse 59, 6020, Innsbruck, Austria. Paul.Debbage@i-med.ac.at.
Innsbruck Medical University · ATUniversität Innsbruck · ATMalmö University · SE

Funding

Oesterreichische Nationalbank Projects 9273, 10844, 11574 and 13096
6 · The paper itself

Abstract

This multidisciplinary study examined the pharmacokinetics of nanoparticles based on albumin-DTPA-gadolinium chelates, testing the hypothesis that these nanoparticles create a stronger vessel signal than conventional gadolinium-based contrast agents and exploring if they are safe for clinical use. Nanoparticles based on human serum albumin, bearing gadolinium and designed for use in magnetic resonance imaging, were used to generate magnet resonance images (MRI) of the vascular system in rats ("blood pool imaging"). At the low nanoparticle doses used for radionuclide imaging, nanoparticle-associated metals were cleared from the blood into the liver during the first 4 h after nanoparticle application. At the higher doses required for MRI, the liver became saturated and kidney and spleen acted as additional sinks for the metals, and accounted for most processing of the nanoparticles. The multiple components of the nanoparticles were cleared independently of one another. Albumin was detected in liver, spleen, and kidneys for up to 2 days after intravenous injection. Gadolinium was retained in the liver, kidneys, and spleen in significant concentrations for much longer. Gadolinium was present as significant fractions of initial dose for longer than 2 weeks after application, and gadolinium clearance was only complete after 6 weeks. Our analysis could not account quantitatively for the full dose of gadolinium that was applied, but numerous organs were found to contain gadolinium in the collagen of their connective tissues. Multiple lines of evidence indicated intracellular processing opening the DTPA chelates and leading to gadolinium long-term storage, in particular inside lysosomes. Turnover of the stored gadolinium was found to occur in soluble form in the kidneys, the liver, and the colon for up to 3 weeks after application. Gadolinium overload poses a significant hazard due to the high toxicity of free gadolinium ions. We discuss the relevance of our findings to gadolinium-deposition diseases.

Indexed as

Magnetic Resonance ImagingAlbuminsAnimalsChelating AgentsContrast MediaFemaleGadolinium DTPAInjections, IntravenousMaleMiceMice, Inbred BALB CNanoparticlesRatsRats, Sprague-DawleyTissue Distributionalbumin-(gadolinium-DTPA)AlbuminsChelating AgentsContrast MediaGadolinium DTPAAlbumin nanoparticlesImmunohistochemistryMRI contrast medium gadoliniumPharmacokineticsQuantitative chemical analysisRadiolabeling

Identifiers

PMID33040183
OpenAlexW3092310286

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.